Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.48 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | TSHR | P16473 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | PLAU | P00749 | 1/20 | 0.42 |
| ▸ | S100A4 | P26447 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.38 |
| ▸ | PTPRC | P08575 | 1/20 | 0.38 |
| ▸ | ERN1 | O75460 | 1/20 | 0.38 |
| ▸ | NOS1 | P29475 | 1/20 | 0.38 |
| ▸ | NOS2 | P35228 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5780887 | 0.87 | TDP1 (0.56) | TDP1GPR35ALDH1A1TSHRSMN1; SMN2 | |
| SCHEMBL244915 | 0.87 | TDP1 (0.44) | TDP1GPR35ALDH1A1TSHRSMN1; SMN2 | |
| SCHEMBL25310 | 0.81 | HSD17B10 (0.50) | TDP1GPR35ALDH1A1TSHRSMN1; SMN2 | |
| SCHEMBL55225 | 0.80 | GPR35 (0.55) | TDP1GPR35ALDH1A1TSHRSMN1; SMN2 | |
| SCHEMBL28059536 | 0.78 | SMN1; SMN2 (0.47) | TDP1GPR35ALDH1A1TSHRSMN1; SMN2 | |
| SCHEMBL28175713 | 0.78 | TSHR (0.60) | TDP1GPR35ALDH1A1TSHRSMN1; SMN2 | |
| SCHEMBL10825048 | 0.78 | TDP1 (0.47) | TDP1GPR35ALDH1A1TSHRSMN1; SMN2 | |
| SCHEMBL5682648 | 0.78 | GPR35 (0.67) | TDP1GPR35ALDH1A1TSHRSMN1; SMN2 | |
| SCHEMBL5222485 | 0.78 | TDP1 (0.47) | TDP1GPR35ALDH1A1TSHRSMN1; SMN2 | |
| SCHEMBL5160633 | 0.78 | TDP1 (0.67) | TDP1GPR35ALDH1A1TSHRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1989004672-A1 | DERIVATIVES OF LINCOSAMINIDE ANTIBIOTICS | THE UPJOHN COMPANY (US) | 1989-06-01 | — | — | WO | claimed |
| US-4378803-A | Process for producing antithrombogenic vinyl acetate polymer or hydrolyzate thereof | UNITIKA, LTD. (JP) | 1983-04-05 | — | — | US | claimed |
| US-10065133-B2 | Separation material comprising phosphoryl choline derivatives | PENTRACOR GMBH (DE) | 2018-09-04 | — | — | US | disclosed |
| US-9671396-B2 | Solid substrate comprising array of dendrons and methods for using the same | PARK JOON WON (KR) | 2017-06-06 | — | — | US | disclosed |
| EP-3041852-B1 | SEPARATION MATERIAL COMPRISING PHOSPHORYL CHOLINE DERIVATIVES | PENTRACOR GMBH (DE) | 2017-05-31 | — | — | EP | disclosed |
| US-20170120163-A1 | SEPARATION MATERIAL COMPRISING PHOSPHORYL CHOLINE DERIVATIVES | PENTRACOR GMBH (DE) | 2017-05-04 | — | — | US | disclosed |
| EP-3041852-A1 | SEPARATION MATERIAL COMPRISING PHOSPHORYL CHOLINE DERIVATIVES | Pentracor GmbH (DE) | 2016-07-13 | — | — | EP | disclosed |
| US-9389227-B2 | Solid substrate comprising array of dendrons and methods for using the same | POSCO (KR) | 2016-07-12 | — | — | US | disclosed |
| EP-2957563-A1 | Separation material comprising phosphoryl choline derivatives | Pentracor GmbH (DE) | 2015-12-23 | — | — | EP | disclosed |
| WO-2015193504-A1 | SEPARATION MATERIAL COMPRISING PHOSPHORYL CHOLINE DERIVATIVES | PENTRACOR GMBH (DE) | 2015-12-23 | — | — | WO | disclosed |
| US-9201067-B2 | Size-controlled macromolecule | POSCO (KR) | 2015-12-01 | — | — | US | disclosed |
| US-4342750-A | Method for treating benign prostatic hypertrophy with N-acyl amphotericin B | SCHMID LABS., INC. (US) | 1982-08-03 | — | — | US | disclosed |
| US-4292310-A | BY MOUTH; ANTICHOLESTEROL AND ANTILIPEMIC AGENTS | LONDON INTERNATIONAL U.S. HOLDINGS, INC. | 1981-09-29 | — | — | US | disclosed |
| US-4163050-A | Method of treating hypercholesterolemia with candimycin | SCHMID LABORATORIES, INC. (US) | 1979-07-31 | — | — | US | disclosed |
| US-4067966-A | Method of treating hypercholesterolemia with antibiotic SCH-16656 | SCHMID LABORATORIES, INC. (US) | 1978-01-10 | — | — | US | disclosed |
| US-4039659-A | METHOD FOR TREATING HYPERCHOLESTEROLEMIA WITH LEVORIN | SCHMID LABORATORIES, INC. (US) | 1977-08-02 | — | — | US | disclosed |
| US-3978079-A | DIPHTHALIMIDO, DISUCCINIMIDO AND DIMALEIMIDO OXALATES | AMERICAN CYANAMID COMPANY (US) | 1976-08-31 | — | — | US | disclosed |
| US-3966910-A | Method for treating hypercholesterolemia with mediocidin | SCHMID LABORATORIES, INC. (US) | 1976-06-29 | — | — | US | disclosed |
| US-3966911-A | Method for treating hypercholesterolemia with N-acetyl candicidin | SCHMID LABORATORIES, INC. (US) | 1976-06-29 | — | — | US | disclosed |
| US-3954971-A | Method of treating prostatic hypertrophy with N-acetyl candicidin | SCHMID LABORATORIES, INC. (US) | 1976-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170120163-A1 | SEPARATION MATERIAL COMPRISING PHOSPHORYL CHOLINE DERIVATIVES | CHKA, PHOSPHO1, C3AR1 | TDP1 3114/4885GPR35 1454/4885ALDH1A1 4540/4885 |
| US-10065133-B2 | Separation material comprising phosphoryl choline derivatives | CHKA, PHOSPHO1, CHKB | TDP1 3115/4885GPR35 1615/4885ALDH1A1 4590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.